<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01583244</url>
  </required_header>
  <id_info>
    <org_study_id>IM101-300</org_study_id>
    <nct_id>NCT01583244</nct_id>
  </id_info>
  <brief_title>Korean Post-marketing Surveillance for Orencia®</brief_title>
  <official_title>Korean Post-marketing Surveillance for Orencia®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this post-marketing surveillance is to investigate and confirm the type and
      incidence of newly identified adverse events and any other factors affecting safety and
      efficacy of Orencia® so that the regulatory authority can manage the marketing approval
      properly.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Time Perspective: Prospective / Retrospective(On-treatment)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events occurrence</measure>
    <time_frame>30 days after last dose of study drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events and Serious Adverse Events</measure>
    <time_frame>30 days after last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of Orencia® measured by swollen joint counts and tender joint counts in the subject treated with the surveillance drug, patient-assessed pain, APR, patient-assessed global health, physician-assessed global disease activity</measure>
    <time_frame>24 weeks of registration</time_frame>
    <description>* APR = acute phase reactants</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">701</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Patients with active rheumatoid arthritis</arm_group_label>
    <description>Patients aged 6 years and over who have moderate-to-severe active rheumatoid arthritis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>No Intervention (subjects were previously treated with Orencia®)</intervention_name>
    <description>No Intervention</description>
    <arm_group_label>Patients with active rheumatoid arthritis</arm_group_label>
    <other_name>Abatacept</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients aged 6 years and over who have moderate-to-severe active rheumatoid arthritis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Patients must be diagnosed with: Adult Rheumatoid arthritis (RA): adult patients with
             moderate-to-severe active RA

        Or

          -  Juvenile idiopathic RA: juvenile patients aged 6 years and older with
             moderate-to-severe active RA

        Exclusion Criteria:

          -  Children aged &lt;6 years

          -  Pregnant or lactating women

          -  Patients who are participating in another study

          -  Patients known to be hypersensitive to the active component of the surveillance drug
             or any other component of the surveillance drug

          -  Patients who had a positive tuberculosis screening test but were not treated with
             standard therapy before participating in the study

          -  Patients who have a positive hepatitis virus test

          -  Patients who were given a live vaccine concurrently with the surveillance drug or are
             expected to be given a live vaccine again within 3 months after discontinuation of the
             surveillance drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seoul</city>
        <zip>110-756</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2012</study_first_submitted>
  <study_first_submitted_qc>April 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2012</study_first_posted>
  <last_update_submitted>May 10, 2016</last_update_submitted>
  <last_update_submitted_qc>May 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

